Bucillamine low dose for Coronavirus

"Unfortunately, this particular clinical trial is no longer recruiting patients. Although, there are 1144 other medical studies currently looking for volunteers. This particular study was originally posted on November 27th, 2020 and was last updated on October 25th, 2022."

"This study has completed recruitment for its clinical trial. The listing was first posted on November 27th, 2020 and was last edited on October 25th, 2022. For those looking for other studies, there are 1142 active studies searching for patients with covid-19 and 2 studies for Bucillamine low dose admitting patients."

"Bucillamine low dose has been studied in multiple Phase 3 trials, meaning that there is some efficacy data and multiple rounds of safety data. Our team at Power estimates its safety to be a 3 on a scale from 1 to 3."

"To be eligible for this coronavirus treatment clinical trial, patients must have an active covid-19 infection and be between 18-80 years old. A total of 1000 people are needed for the study."

"Eligibility for this trial starts at 18 years old and caps at 80 years old."

"In 2007, the Department of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University first investigated the efficacy of bucillamine. Since then, there have been 18268 completed clinical trials. At the moment, there are 2 ongoing clinical trials, both based in Coral Gables, Florida."